Should I Buy DBVT? DBVT 2026 Analysis

Should You Buy Dbv Technologies SA (DBVT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

21.260

1 Day change

-0.93%

52 Week Range

26.180

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient trader: the stock is gapping up (pre-market +10% / regular session +2.76%) into nearby resistance without supportive proprietary signals, which raises near-term pullback risk.
Longer-term setup remains attractive (Phase 3 success + multiple price-target raises), but the current entry is more “chasey” than optimal.
Intellectia Proprietary Trading Signals
AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Trend: Bullish structure with moving averages stacked positively (SMA_5 > SMA_20 > SMA_200), suggesting the broader trend is up.
Momentum: MACD histogram is slightly negative (-0.0076) but negatively contracting, implying downside momentum is fading, not accelerating.
RSI(6) at ~60.2: neutral-to-mildly bullish, not overbought, but not deeply oversold either.
Key levels: Pivot 23.305 (price ~23.365 is sitting on pivot = decision point). Resistance at R1 24.807 then R2 25.734; support at S1 21.804 then S2 20.877.
Pattern-based forward view provided: 60% chance of small downside over 1D/1W/1M (approx. -1.17% / -0.51% / -0.92%), which argues against buying a gap-up.

Positive Catalysts

- Major clinical catalyst already validated: Phase 3 VITESSE study results described as successful; supports planned BLA submission in 1H 2026.
- Strong Street reaction: multiple firms raised price targets materially after the Phase 3 readout (bullish sentiment reinforcement).
- Potential funding tailwind mentioned by analysts: success triggers accelerated exercise dynamics for outstanding warrants, implying possible cash infusion that could help fund launch planning.
- Relative strength vs market today (S&P 500 down ~0.71% while DBVT is up).

Neutral/Negative Catalysts

- Near-term trading risk: large pre-market jump increases the odds of profit-taking/mean reversion without confirming buy signals (no AI Stock Picker/SwingMax support).
- No fresh news in the past week beyond prior clinical/analyst developments, so incremental catalysts may be limited immediately.
- Biotech execution/regulatory timeline risk remains: the next major step (BLA submission/priority review dynamics) is still in the future (1H 2026).

Financial Performance

Latest quarter: 2025/Q3.
Revenue: 2.774M, +158.77% YoY (strong growth off a small base).
Net income: -33.164M, improved +8.94% YoY (still meaningfully loss-making).
EPS: -0.24, -25% YoY (worse per-share performance YoY despite net loss improving, likely driven by share count/other factors).
Gross margin: 100% (typical for the company’s current stage; not the key driver vs cash burn and clinical progress).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend is sharply positive: coverage initiations and multiple price-target increases clustered around the Phase 3 VITESSE success.
Latest notable PTs/ratings: Cantor $48 (Overweight), Guggenheim $51 (Buy), Citizens $45 (Outperform), H.C. Wainwright $40 (Buy).
Wall Street “pros” view: Phase 3 is a major de-risking event; clearer path toward BLA submission in 1H 2026 and eventual commercialization.
Wall Street “cons” view: valuation depends heavily on regulatory execution and commercialization timing; near-term stock moves can overshoot on biotech momentum.
Influential/political trading: No recent congress trading data available; hedge funds and insiders flagged as neutral (no significant recent trend).

5 Analyst Rating

Wall Street analysts forecast DBVT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DBVT is 46.4 USD with a low forecast of 40 USD and a high forecast of 51 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 21.460

Low

Averages

46.4

High

Current: 21.460

Low

Averages

46.4

High

Cantor Fitzgerald

Kristen Kluska

upgrade

$42 -> $48

AI Analysis

2025-12-17

Reason

Cantor Fitzgerald

Kristen Kluska

Price Target

$42 -> $48

AI Analysis

2025-12-17

upgrade

Reason

Cantor Fitzgerald analyst Kristen Kluska raised the firm's price target on DBV Technologies to $48 from $42 and keeps an Overweight rating on the shares. DBV Technologies announced successful results from the Phase 3 VITESSE study of VIASKIN, with open-label extension enrollment trends in-line with previous studies and compliance "quite high" at over 96%, the analyst tells investors in a research note. Cantor is confident that these data check off the final box for a BLA submission in this patient population.

H.C. Wainwright

Buy

maintain

$35 -> $40

2025-12-17

Reason

H.C. Wainwright

Price Target

$35 -> $40

2025-12-17

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on DBV Technologies to $40 from $35 and keeps a Buy rating on the shares. The company's Phase 3 VITESSE trial in 4-7 year old peanut-allergic children "represents a clear execution win that we believe materially de-risks the Viaskin program," the analyst tells investors in a research note. The firm says the positive readout supports an application submission in the first half of 2026 and strengthens its confidence in a straightforward regulatory path.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for DBVT

Unlock Now

DBVT Should I Buy

DBVT Should I Buy

Should You Buy Dbv Technologies SA (DBVT) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch